Inflammatix, Inc.
Sunnyvale, CA
- UEI
- WK9MLMSHBVL3
- CAGE
- 7Q4D9
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 540 Oakmead Pkwy, Sunnyvale, CA 94085, USA
- Website
- inflammatix.com
- Founded
- 2016
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$1 |
| FY2024 | $0 |
| FY2023 | $2,352,124 |
Contract awards
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cytovale Inc. | South San Francisco, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Rizlab Health Inc. | Princeton, NJ | 541330 Engineering Services |
| Aptitude Medical Systems Inc. | Goleta, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Visby Medical, Inc. | San Jose, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Helixbind, Inc. | Boxborough, MA | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Inflammatix, Inc. is a molecular diagnostics company that develops rapid point of care diagnostic tests by analyzing the immune system to address major clinical health challenges. Through federal contracts and grants, Inflammatix provides research, development, and testing services related to diagnostic solutions for acute infections and sepsis.
Inflammatix has been awarded over $29 million in federal contracts from the Department of Health and Human Services to support the development of diagnostic cartridges and host-response prognostic tools. This includes contracts to develop the Triverity cartridge for detecting infection severity and a host-response test called HOSTDX-Sepsis. Additional federal contracts have supported Inflammatix's development of solutions for COVID-19 diagnostics and therapeutics.
Through federal grants, Inflammatix conducts research on diagnostic tests for conditions such as sepsis, myocardial infarction, and inflammatory bowel disease. A $4 million National Institutes of Health grant is funding validation and development of a rapid blood test to classify sepsis patients into subgroups for improved treatment plans. Another NIH grant supported development of a gene expression test to predict response to anti-TNF therapies for inflammatory bowel disease. Inflammatix leverages machine learning and meta-analysis approaches in developing these novel diagnostic solutions.
Quick answers
Is Inflammatix, Inc. registered in SAM.gov?
Yes. Inflammatix, Inc.'s SAM.gov registration is active through April 9, 2027.
How much has Inflammatix, Inc. received in federal contracts?
Federal contracts obligated $2,352,123 to Inflammatix, Inc. in fiscal years 2023 through 2027.
What is Inflammatix, Inc.'s most recent federal award?
Inflammatix, Inc.'s most recent federal grant award is Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with… (R43HL167483), from National Heart Lung and Blood Institute (NIH), on July 1, 2023.
On GovTribe
See Inflammatix, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors